Atopic dermatitis: ruxolitinib cream shows benefits for pruritus and QoL in phase 2 trial

  • Kim BS & al.
  • J Am Acad Dermatol
  • 11 Feb 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Ruxolitinib cream, a Janus kinase inhibitor, was associated with reduced itch and improved QoL for patients with atopic dermatitis (AD) in a phase 2 randomized controlled trial.

Why this matters

  • AD is associated with significant pruritus and impaired QoL.

Key results

  • Ruxolitinib cream 1.5% twice daily was associated with higher mean improvement rates compared with vehicle:
    • Within 36 hours: 42.5% vs 13.6% (P<.01>
    • At week 8: 68.5% vs 17.6% (P<.0001>
  • Itch reduction was associated with reduced QoL burden (P<.001>
  • Ruxolitinib cream 1.5% twice daily was associated with improved QoL (Skindex-16 overall score) vs vehicle at:
    • Week 2: 63.5% vs 10.5% (P<.001>
    • Week 8: 73.2% vs 19.7% (P<.001>

Study design

  • 307 patients with AD with Investigator’s Global Assessment score of 2/3 and 3%-20% affected body surface area were randomly allocated to ruxolitinib cream (1.5% twice daily, 1.5% once daily, 0.5% once daily, or 0.15% once daily), vehicle twice daily, or triamcinolone cream 0.1% twice daily/vehicle for 8 weeks.
  • Funding: Incyte Corporation.

Limitations

  • Small patient sample size in each group.
  • Short trial duration.
  • Facial lesions not treated.